Article
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
Clinical and molecular hepatology - 1 Dec 2016
Lee Hye Won, Park Jun Yong, Kim Beom Kyung, Kim Moon Young, Lee Jung Il, Kim Young Suk, Yoon Ki Tae, Han Kwang-Hyub, Ahn Sang Hoon
Abstract excerpt
BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). METHODS: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.